{"organizations": [], "uuid": "ed41feb3d2783fcdb93f890abfd04b8404c03879", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/", "section_title": "Business &amp; Financial News, U.S &amp; International Breaking News | Reuters", "url": "https://www.reuters.com/article/us-ftc-impax-laboratories/impax-labs-antitrust-complaint-dismissed-at-federal-trade-commission-idUSKCN1IP2YH", "country": "US", "domain_rank": 408, "title": "Impax Labs antitrust complaint dismissed at Federal Trade Commission", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.845, "site_type": "news", "published": "2018-05-25T00:44:00.000+03:00", "replies_count": 0, "uuid": "ed41feb3d2783fcdb93f890abfd04b8404c03879"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-ftc-impax-laboratories/impax-labs-antitrust-complaint-dismissed-at-federal-trade-commission-idUSKCN1IP2YH", "ord_in_thread": 0, "title": "Impax Labs antitrust complaint dismissed at Federal Trade Commission", "locations": [], "entities": {"persons": [{"name": "lisa lambert", "sentiment": "none"}, {"name": "endo", "sentiment": "none"}, {"name": "bill berkrot", "sentiment": "none"}], "locations": [{"name": "washington", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "federal trade commission", "sentiment": "negative"}, {"name": "impax labs", "sentiment": "negative"}, {"name": "impax laboratories inc", "sentiment": "none"}, {"name": "impax", "sentiment": "none"}, {"name": "endo pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 24, 2018 / 4:44 PM / Updated 15 minutes ago Impax Labs antitrust complaint dismissed at Federal Trade Commission Reuters Staff 1 Min Read\nWASHINGTON (Reuters) - An administrative law judge at the Federal Trade Commission on Thursday dismissed the agencyâ€™s antitrust complaint against generic drugmaker Impax Laboratories Inc.\nThe agency had alleged that in June 2010 Impax illegally agreed to refrain from marketing for three years a generic version of an extended-release opioid manufactured by Endo Pharmaceuticals ( ENDP.O ), and received more than $112 million in exchange from Endo.\nBut the in-house judge said there was not sufficient proof that the companies violated antitrust laws and that Impax could have manufactured a generic of the painkiller before 2013. Reporting by Lisa Lambert; Editing by Bill Berkrot", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-25T00:44:00.000+03:00", "crawled": "2018-05-24T20:09:52.041+03:00", "highlightTitle": ""}